C-Met

HUTCHMED and AstraZeneca Initiate Phase II Trial of ORPATHYS® in Patients with MET Amplified Gastric Cancer

Retrieved on: 
Wednesday, July 28, 2021
Enzymes, Tyrosine kinase receptors, Companies, Tyrosine kinase inhibitor, AstraZeneca, Tyrosine kinase, C-Met, TKI, Quinazolines, Pyrrolidines

Patients whose tumors harbor MET amplification were treated with ORPATHYS monotherapy, reporting an ORR of 50% (10/20, 95% CI: 28.0, 71.9).

Key Points: 
  • Patients whose tumors harbor MET amplification were treated with ORPATHYS monotherapy, reporting an ORR of 50% (10/20, 95% CI: 28.0, 71.9).
  • ORPATHYS is an oral, potent, and highly selective MET tyrosine kinase inhibitor (TKI) that has demonstrated clinical activity in advanced solid tumors.
  • In 2011, following its discovery and initial development by HUTCHMED, AstraZeneca and HUTCHMED entered a global licensing agreement to jointly develop and commercialize ORPATHYS.
  • Joint development in China is led by HUTCHMED, while AstraZeneca leads development outside of China.

Surrozen Presents Data at 2021 International Liver Conference for Wnt-Modulating Antibody SZN-043

Retrieved on: 
Friday, June 25, 2021
Branches of biology, Biology, Signal transduction, Glycoproteins, Evolutionary developmental biology, Genes, Wnt signaling pathway, C-Met, Immunoglobulin G

The one oral presentation and three poster presentations discussed data from studies of SZN-043, Surrozens hepatocyte-targeted R-spondin mimetic, in mice and various disease models.

Key Points: 
  • The one oral presentation and three poster presentations discussed data from studies of SZN-043, Surrozens hepatocyte-targeted R-spondin mimetic, in mice and various disease models.
  • SZN-043 showed target-mediated drug disposition and pharmacokinetics that were consistent with that of an IgG-based molecule binding to the hepatocyte membrane protein ASGR1.
  • Surrozen is a biotechnology company discovering and developing drug candidates to selectively modulate the Wnt pathway.
  • Investors and security holders of Surrozen are advised to read, when available, the proxy statement/prospectus in connection with the written consent of Surrozen stockholders.

HUTCHMED announces savolitinib approved in China for patients with lung cancer with MET exon 14 skipping alterations

Retrieved on: 
Tuesday, June 22, 2021
Tyrosine kinase receptors, Lung cancer, Organic compounds, Quinazolines, Chemical compounds, Non-small-cell lung carcinoma, Tyrosine kinase, C-Met, Branches of biology, Tyrosine kinase inhibitors, Chloroarenes, Icotinib

Approximately 2-3% of newly diagnosed NSCLC patients have MET exon skipping 14 alterations, a specific genetic mutation.

Key Points: 
  • Approximately 2-3% of newly diagnosed NSCLC patients have MET exon skipping 14 alterations, a specific genetic mutation.
  • Savolitinib is an oral, potent and selective MET TKI that has demonstrated clinical activity in advanced solid tumors.
  • It blocks atypical activation of the MET receptor tyrosine kinase pathway that occurs because of mutations (such as exon 14 skipping alterations).
  • HUTCHMED is responsible for the manufacturing and supply of savolitinib, and AstraZeneca is responsible for its commercialization in China and worldwide.

The U.S. FDA Approved IND Application to Investigate Combination of Asieris' APL-1202 and BeiGene's Tislelizumab as Neoadjuvant Therapy for MIBC Patients

Retrieved on: 
Tuesday, June 15, 2021
Drugs, Immunology, Medical specialties, Orphan drugs, Immune system, Monoclonal antibodies, Programmed cell death protein 1, Tumor microenvironment, Tislelizumab, C-Met

APL-1202 is an orallyavailable reversible MetAP2 Inhibitor with anti-angiogenic, anti-tumor activities and can also modulate tumor immune microenvironment.

Key Points: 
  • APL-1202 is an orallyavailable reversible MetAP2 Inhibitor with anti-angiogenic, anti-tumor activities and can also modulate tumor immune microenvironment.
  • Tislelizumab is a humanized IgG4 anti-PD-1 monoclonal antibody specifically designed to minimize binding to FcR on macrophages.
  • "We are very pleased that FDA approved the IND application for oral APL-1202 in combination with tislelizumabas a neoadjuvant therapy in MIBC patients," said Dr. Xue Yong, MD, PhD, Chief Medical Officer at Asieris.
  • We aim to establish an outstanding portfolio that covers diagnosis and treatment in a bid to benefit more patients in China and globally.

ONK Therapeutics Secures Exclusive Global License to Patent for CISH Knockout in NK Cells for the Treatment of Cancer, from Australia’s WEHI

Retrieved on: 
Thursday, May 27, 2021
Oncology, Health, Clinical trials, Research, Science, Pharmaceutical, Biotechnology, Branches of biology, Immune system, Lymphocytes, Natural killer cell, CISH, C-Met, Biology

Deletion of CISH in NK cells leads to an improved metabolic profile, greatly enhances their proliferation, cytotoxicity, and persistence.

Key Points: 
  • Deletion of CISH in NK cells leads to an improved metabolic profile, greatly enhances their proliferation, cytotoxicity, and persistence.
  • This patent agreement builds on and strengthens the broad IP we have created at ONK Therapeutics against multiple NK cell checkpoints, added Prof ODwyer.
  • Improving the metabolic fitness of NK cells to enhance glycolysis and oxidative phosphorylation is important for optimizing the anti-tumor activity of NK cells, especially against solid tumors(2-3).
  • Under the terms of the agreement, ONK Therapeutics has secured exclusive global rights to WEHIs patent covering the use of human NK cells lacking CISH for the purposes of researching, developing, manufacturing and commercializing NK cell therapies.

EGFR Inhibitors-Induced Skin Disorders Market Will Exhibit Notable CAGR of 18.25% During the Study Period [2018-2030], Speculates DelveInsight

Retrieved on: 
Thursday, April 8, 2021
Tyrosine kinase receptors, Epidermal growth factor receptor, Oncogenes, Quinazolines, Branches of biology, Organic compounds, C-Met, Tyrosine kinase inhibitors, Enzymes, Amines, Targeted covalent inhibitors, Gefitinib

The EGFR Inhibitors-Induced Skin Disorders market report also proffers an analysis of the current EGFR Inhibitors-Induced Skin Disorders treatment algorithm/practice, market drivers, market barriers, and unmet medical needs.

Key Points: 
  • The EGFR Inhibitors-Induced Skin Disorders market report also proffers an analysis of the current EGFR Inhibitors-Induced Skin Disorders treatment algorithm/practice, market drivers, market barriers, and unmet medical needs.
  • The EGFR Inhibitors-Induced Skin Disorders market has a critical unmet need for approved therapies specific to EGFR inhibitor-induced skin disorders.
  • EGFR inhibitors-Induced Skin Disorders pipeline possesses potential drugs in mid-stage developments to be launched shortly.
  • The EGFR Inhibitors-Induced Skin Disorders market has a critical unmet need for approved therapies.

EGFR Inhibitors-Induced Skin Disorders Market Will Exhibit Notable CAGR of 18.25% During the Study Period [2018-2030], Speculates DelveInsight

Retrieved on: 
Thursday, April 8, 2021
Tyrosine kinase receptors, Epidermal growth factor receptor, Oncogenes, Quinazolines, Branches of biology, Organic compounds, C-Met, Tyrosine kinase inhibitors, Enzymes, Amines, Targeted covalent inhibitors, Gefitinib

The EGFR Inhibitors-Induced Skin Disorders market report also proffers an analysis of the current EGFR Inhibitors-Induced Skin Disorders treatment algorithm/practice, market drivers, market barriers, and unmet medical needs.

Key Points: 
  • The EGFR Inhibitors-Induced Skin Disorders market report also proffers an analysis of the current EGFR Inhibitors-Induced Skin Disorders treatment algorithm/practice, market drivers, market barriers, and unmet medical needs.
  • The EGFR Inhibitors-Induced Skin Disorders market has a critical unmet need for approved therapies specific to EGFR inhibitor-induced skin disorders.
  • EGFR inhibitors-Induced Skin Disorders pipeline possesses potential drugs in mid-stage developments to be launched shortly.
  • The EGFR Inhibitors-Induced Skin Disorders market has a critical unmet need for approved therapies.

Angion Provides Corporate Update and Reports Fourth Quarter and Full Year 2020 Financial Results

Retrieved on: 
Tuesday, March 30, 2021
Tyrosine kinase receptors, Branches of biology, Cell biology, Hepatocyte growth factor, Biology, C-Met, Tyrosine kinase, Receptor tyrosine kinase

This a very exciting time for Angion, said Dr. Jay R. Venkatesan, Angions President and Chief Executive Officer.

Key Points: 
  • This a very exciting time for Angion, said Dr. Jay R. Venkatesan, Angions President and Chief Executive Officer.
  • In 2020, we advanced the clinical development of our lead program ANG-3777, a small molecule HGF mimetic, being investigated in acute organ injuries, continued Dr. Venkatesan.
  • Angion is also currently evaluating ANG-3070, a tyrosine kinase receptor inhibitor for the treatment of fibrotic disease, in Phase 1.
  • Angion undertakes no obligation to update any forward-looking statement in this press release, except as required by law.

RAPT Therapeutics to Report Promising Preclinical Studies Supporting its Pipeline of Immunotherapy Platforms at AACR

Retrieved on: 
Wednesday, March 10, 2021
Branches of biology, Cytokines, Cell biology, Immune system, Clusters of differentiation, Chemokine receptors, CCL17, CCL22, CCR4, Regulatory T cell, Mesothelioma, C-Met

Treg express CCR4 and migrate toward CCL17 and CCL22 which are frequently upregulated in a subset of tumors or increased following immunotherapy.

Key Points: 
  • Treg express CCR4 and migrate toward CCL17 and CCL22 which are frequently upregulated in a subset of tumors or increased following immunotherapy.
  • In a murine mesothelioma model, a combination of CAR- T-cells plus CCR4 antagonist significantly slowed tumor growth and significantly improved survival compared to untreated control.
  • RAPTs small-molecule compounds demonstrated potent inhibition of HPK1 in biochemical assays, reduction of levels of phosphorylated SLP76 and concomitant increase in IL-2 production.
  • Recent advances in cancer metabolism suggest that targeting amino acid metabolism represents a promising strategy for the development of novel therapeutic agents.

Cytovia Therapeutics’ Management to Present at Three Upcoming Conferences in March

Retrieved on: 
Monday, March 8, 2021
Clinical medicine, Branches of biology, Medicine, Immune system, Cancer immunotherapy, Chimeric antigen receptor T cell, Gene therapy, Leukemia, Natural killer cell, Immunotherapy, C-Met, Antigen-presenting cell

Cytovia aims to accelerate patient access to transformational cell therapies and immunotherapies, addressing several of the most challenging unmet medical needs in cancer.

Key Points: 
  • Cytovia aims to accelerate patient access to transformational cell therapies and immunotherapies, addressing several of the most challenging unmet medical needs in cancer.
  • Cytovias proprietary multi-specific antibody platform has been customized to engage and activate NK Cells at the tumor site.
  • Chimeric Antigen Receptors (CAR) are fusion proteins that combine an extracellular antigen recognition domain with an intracellular co-stimulatory signaling domain.
  • In addition, CAR-NKs are naturally allogeneic, available off-the-shelf and may be able to be administered on an outpatient basis.